oral treatment articles & resources on Made-in-China.com

Scientists Have Moved a Step Closer to an "Obesity Drug"

Feb 28, 2014

Scientists have moved a step closer to an "obesity drug" that may block the effects of diets high in fat and sugar, according to research from the University of Queensland in Brisbane. The findings, published in the December 2013 issue ...

Tags: Obesity Pill, University of Queensland in Brisbane

FDA Has Approved Ospemifene Tablets for The Treatment of Moderate

Feb 27, 2013

Food and Drug Administration (FDA) has approved US-based pharmaceutical company Shionogi's Osphena (ospemifene) tablets for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy ...

Tags: FDA, Dyspareunia, Medicine

Aubagio Has Shown Significant Efficacy Across Key Measures of MS Disease Activity

Dec 5, 2012

The FDA has approved Genzyme, a Sanofi company, Aubagio (teriflunomide) as a new once-daily, oral treatment indicated for relapsing forms of multiple sclerosis (MS). Aubagio, an immunomodulator with anti-inflammatory properties, has shown ...

Tags: Aubagio, teriflunomide, new once-daily, oral treatment

Janssen-Cilag International Submitted a Marketing Authorisation Application

Dec 5, 2012

Janssen-Cilag International has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) seeking conditional approval to use the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as ...

Tags: investigational drug bedaquiline, multi-drug resistant tuberculosis

Exjade Has Received Positive Opinion From CHMP of EMA

Dec 4, 2012

Novartis' Exjade has received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Exjade is used to treat chronic iron overload requiring chelation therapy when ...

Tags: Medicinal Products, iron overload, CHMP recommendation

Janssen Biotech Signed a License Agreement for The Worldwide Development

Nov 29, 2012

Janssen Biotech has signed a license agreement with Astellas Pharma for the worldwide development and commercialization of ASP015K, except in Japan. Astellas will continue development and commercialization of ASP015K in Japan. ASP015K, ...

Tags: Janssen Biotech, Astellas Pharma, license agreement, ASP015K